搜尋
Karyopharm Therapeutics Inc
KPTI添加自選
7.410USD
+0.320+4.51%
收盤 07-24 16:00（美東）報價延遲15分鐘
64.48M總市值
虧損本益比TTM
關於 Karyopharm Therapeutics Inc 公司
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Karyopharm Therapeutics Inc簡介
公司代碼KPTI
公司名稱Karyopharm Therapeutics Inc
上市日期Nov 06, 2013
CEOPaulson (Richard A)
員工數量279
證券類型Ordinary Share
年結日Nov 06
公司地址85 Wells Avenue
城市NEWTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02459
電話16176580600
網址https://karyopharm.com/
公司代碼KPTI
上市日期Nov 06, 2013
CEOPaulson (Richard A)
Karyopharm Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
13.01K
+4.14%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
12.50K
+3.94%
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
85.25K
+0.51%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
16.41K
+94.47%
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Dr. Deepika R. (Deepa) Pakianathan, Ph.D.
Independent Director
Independent Director
15.51K
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
15.51K
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
15.51K
--
Dr. Zhen Su
Dr. Zhen Su
Independent Director
Independent Director
15.51K
--
常見問題
Karyopharm Therapeutics Inc的前五大股東是誰？
Karyopharm Therapeutics Inc的前五大股東如下：Mr. Michael Mano, J.D.
有多少機構持有Karyopharm Therapeutics Inc(KPTI)的股份？
截至2026Q1，共有236家機構持有Karyopharm Therapeutics Inc的股份，合計持有的股份價值約為14.10M，占公司總股份的62.56% 。與2025Q4相比，機構持股有所增加，增幅為5055019.00。